bibliography 1. ed., new york; marcell dekker;...

Bibliography

Dept. Of Pharmaceutics, JSSCP, Mysore 219

1. Robinson JR, Lee VH. Controlled drug delivery system, 2nd ed., New York;

Marcell Dekker; 2005.

2. Rathbone JM, Jonathan H. Modified release drug delivery technology, 11th

edition, New York; Marcell Dekker. Inc; 2002.

3. Deshpande AA, Rhodes CT, Shah NH. Controlled release drug delivery

systems for prolonged gastric residence, Drug Dev Ind Pharm 1986; 22(6):

531-539.

4. Urquhart J. Performance requirements for controlled release dosage forms:

therapeutical and pharmacological perspectives in. Controlled Release

Pharmaceuticals, American Pharmaceutical Association, Academy of

Pharmaceutical Sciences, Washington, DC, 1981.

5. Sinha VR, Kumria R. Polysaccharides in colon drug delivery Review, Int J

Pharm 2001; 224: 19-38.

6. Van der Lubben IM, Verhoef JC, Borchard G, Junginger HE. Chitosan for

mucosal vaccination. Adv Drug Deliv Rev 2001; 52: 13944.

7. Devika RB, Varsha B. Pokharkar. Studies on effect of pH on cross-linking of

chitosan with sodium tripolyphosphate: A Technical Note. AAPS

PharmSciTech 2006; 7 (2): E1-E6.

8. Future Vaccine Strategies. Available from: www.worldwidevaccines.com

(Accessed on 22/4/2010).

9. Decker MD, Edwards KM. Combination vaccines. In: Vaccines; Orenstein

WA, editors. 3rd ed. Philadelphia: 1999: 508-30.

10. Marirosa M, Daniele V, Laura S, Pizza, M, Rappuoli R. Reverse Vaccinology.

Drug Discovery Today 2003; 8: 459-464.

http://www.worldwidevaccines.com

Bibliography


11. Estevan M, Irache JM, Grillo MJ, Blasco JM, Gamazo C. Encapsulation of

antigenic extracts of Salmonella enterica serovar Abortusovis into polymeric

systems and efficacy as vaccines in mice. Vet Microbiol 2006; 14; 124-32.

12. Borges O, Cordeiro A, Romeijn SG. Uptake studies in rat Peyer's patches,

cytotoxicity and release studies of alginate coated chitosan nanoparticles for

mucosal vaccination. J Control Rel 2006; 114: 348-58.

13. Jung T, Kamm W, Breitenbach A, Kaiserling E, Xiao JX, Kissel T.

Biodegradable nanoparticles for oral delivery of peptides: is there a role for

polymers to affect mucosal uptake? Eur J Pharm Biopharm 2000; 50:147- 60.

14. Sakuma S, Hayashi M, Akashi M. Design of nanoparticles composed of graft

copolymers for oral peptide delivery. Adv Drug Deliv Rev, 2001; 47:2137.

15. Davis S. Biomedical applications of particle engineering. In R. H. R. Coombs

and W. D. Robinson (eds.), Nanotechnology in Medicine and the Biosciences,

Gordon & Breach, Amsterdam, The Netherlands, 1996, 243262.

16. Jaeghere FD, Doelker E, Gurny R. Nanoparticles. Mathiowitz (ed),

Encyclopedia of Controlled Drug Delivery, John Wiley, New York,

1999,641664.

17. Moghimi SM, Hunter AC, Murray JC. Long-circulating and target-specific

nanoparticles: theory to practice. Pharmacol. Rev 2001; 53:283318.

18. Couvreur P, Barratt G, Fattal E, Legrand P, Vauthier C. Nanocapsule

technology: a review. Crit. Rev. Ther Drug Carrier Syst 2002; 19: 99134.

19. Soppimath KS, Aminabhavi TS, Kulkarni AR, Rudzinski WE. Biodegradable

polymeric nanoparticles as drug delivery devices. J Control Rel 2001; 70:1

20.

Bibliography


20. Hans ML and Lowman AM. Biodegradable nanoparticles for drug delivery

and targeting. Curr. Opin. Solid State Mater Sci 2002; 6:319327.

21. Kumar N, Ravikumar MNV, Domb AJ. Biodegradable block copolymers. Adv

Drug Deliv Rev 2001; 53: 23 - 44.

22. Vila A, Sanchez A, Tobio M, Calvo P, Alonso MJ. Design of biodegradable

particles for protein delivery. J Control Rel 2002; 78: 15-24.

23. Mu L, Feng SS. A novel controlled release formulation for the anticancer drug

paclitaxel Taxol (R): PLGA nanoparticles containing vitamin E TPGS. J

Control Rel 2003; 86: 33-48.

24. Yeh P, Ellens H, Smith PL. Physiological considerations in the design of

particulate dosage forms for oral vaccine delivery. Adv Drug Deliv Rev 1998;

34:123133.

25. Lehr CM. Lectin-mediated drug delivery: the second generation of

bioadhesives. J Control Rel 2000; 65:1929.

26. Couvreur P, Dubernet C, Puisieux F. Controlled drug delivery with

nanoparticles: current possibilities and future trends. Eur J Pharm Biopharm

1995; 41:2 - 13.

27. Montasser I, Fessi H, Coleman AW. Atomic force microscopy imaging of

novel type of polymeric colloidal nanostructures. Eur J Pharm Biopharm

2002; 54:281- 4.

28. Tice TR, Gilley RM. Preparation of injectable controlled-release

microcapsules by solvent-evaporation process. J Control Release 1985; 2:343 -

52.

Bibliography


29. Fessi H, Puisieux F, Devissaguet J-P, Ammoury N, Benita S. Nanocapsule

formation by interfacial deposition following solvent displacement. Int J

Pharm 1989; 55:R1- R4.

30. Barichello JM, Morishita M, Takayama K, Nagai T. Encapsulation of

hydrophilic and lipophilic drugs in PLGA nanoparticles by the

nanoprecipitation method. Drug Dev Ind Pharm 1999; 25:471- 6.

31. Galindo-Rodriguez S, Alle´mann E, Fessi H, Doelker E. Physicochemical

parameters associated with nanoparticle formation in the salting-out,

emulsification-diffusion, and nanoprecipitation methods. Pharm Res 2004;

21:1428- 39.

32. Ganachaud F, Katz JL. Nanoparticles and nanocapsules created using the ouzo

effect: Spontaneous emulsification as an alternative to ultrasonic and high-

shear devices. Chem Phys Chem 2005; 6: 209- 16.

33. Quintanar-Guerrero D, Alle´mann E, Fessi H, Doelker E. Preparation

techniques and mechanism of formation of biodegradable nanoparticles from

preformed polymers. Drug Dev Ind Pharm 1998; 24: 1113-28.

34. Vargas A, Pegaz B, Debefve E, Konan-Kouakou Y, Lange N, Ballini J-P, et

al. Improved photodynamic activity of porphyrin loaded into nanoparticles: an

in vivo evaluation using chick embryos. Int J Pharm 2004; 286:131- 45.

35. Konan YN, Gurny R, Alle´mann E. State of the art in the delivery of

photosensibilizers for photodynamic therapy. Photochem Photobiol B 2002;

66: 89-106.

36. Yoo HS, Oh JE, Lee KH, Park TG. Biodegradable nanoparticles containing

PLGA conjugate for sustained release. Pharm Res 1999; 16:1114- 8.

Bibliography


37. Perez C, Sanchez A, Putnam D, Ting D, Langer R, Alonso MJ. Poly(lactic

acid)-poly(ethylene glycol) nanoparticles as new car riers for the delivery of

plasmid DNA. J Control Rel 2001; 75:211- 24.

38. Lu W, Zhang Y, Tan Y-Z, Hu K-L, Jiang X-G, Fu S-K. Cationic albumin-

conjugated pegylated nanoparticles as novel drug carrier for brain delivery. J

Control Rel 2005; 107:428- 48.

39. Saxena V, Sadoqi M, Shao J. Indocyanine green-loaded biodegradable

nanoparticles: preparation, physicochemical characterization and in vitro

release. Int J Pharm 2004; 278:293- 301.

40. El-Shabouri MH. Positively charged nanoparticles for improving the oral

bioavailability of cyclosporin-A. Int J Pharm 2002; 249:101- 8.

41. Piemi MPY, Korner D, Benita S, Marty JP. Positively and negatively charged

submicron emulsions for enhanced topical delivery of antifungal drugs. J

Control Rel 1999; 58:177.

42. Yang S, Zhu J, Lu Y, Liang B, Yang C. Body distribution of camptothecin

solidlipid nanoparticles after oral administration. Pharm Res 1999; 16:751.

43. Geze A, Putaux JL, Choisnard L, Jehan P, Wouessidjewe D. Long term shelf

stability of amphiphilic B-cyclodextrin nanospheres suspensions monitored by

dynamic light scattering and cryo-transmission electron microscopy. J

Microencapsul 2004; 21:607.

44. Porter CJH, Kaukonen AM, Boyd BJ, Edwards GA, Charman WN.

Susceptibility to lipase mediated digestion reduces the oral bioavailability of

Danazol after administration as a medium chain lipid based microemulsion

formulation. Pharm Res 2004; 21:1405.

Bibliography


45. Moutardier V, Tosini F, Vlieghe P, Cara L, Delpero JR, Clerc T. Colloidal

anticancer drugs bioavailability in oral administration. Int J Pharm 2003;

260:23.

46. Alexiou C, Jurgons R, Schmid RJ, et al. Magnetic drug targeting

biodistribution of the magnetic carrier and the chemotherapeutic agent

Mitoxantrone after loco-regional cancer treatment. J Drug Target 2003;

11:139.

47. Hecq J, Deleers M, Fanara D, et al. Preparation and in vitro/in vivo evaluation

of nanosized crystals for dissolution rate enhancement of UCB-35440-3, a

highly dosed poorly water soluble weak base. Eur J Pharm Biopharm. 2006;

64:360.

48. Cortez RV, Backmann N, Senter PD, et al. Efficient cancer therapy with a

nanobody based conjugate. Cancer Res 2004; 15:2853.

49. Ueno Y, Futagawa H, Takagi Y, Ueno A, Mizushima Y. Drug incorporating

calcium carbonate nanoparticles for a new delivery system. J Control Rel

2005; 103:93.

50. Nanoparticle- based therapeutics in humans: A survey, Nanotechnology, Law

and business, Summer 2008; 135-155.

51. Damge C, Michel C, Aprahamian M, Couvreur P, Devissaguet JP.

Nanocapsules as carriers for oral peptide delivery. J Control Rel 1990; 13:

233-239.

52. Florence AT. The oral absorption of micro and nano particulates: neither

exceptional nor unusual. Pharm Res 1997; 14:259.

53. Delie F. Evaluation of nano and micro particles uptake by the gastrointestinal

tract. Adv Drug Deliv Rev 1998; 34:221.

Bibliography


54. Rodrigues JS, Magalhaes NSS, Coelho LCBB, Couvreur P, Ponchel G, Gref

R. Novel core (polyester)-shell (polysaccharide) nanoparticles: protein loading

and surface modification with lectins. J Control Rel 2003; 92:103.

55. Scholes PD, Coombes AGA, Illum L, Daviz SS, Vert M, Davies MC. The

preparation of sub- 200 nm poly (lactide-co-glycolide) microspheres for site-

specific drug delivery. J Control Rel 1993; 25: 14553.

56. Peltonen L, Koistinen P, Karjalainen M, Hakkinen A, Hirvonen J. The effect

of cosolvents on the formulation of nanoparticles from low-molecularweight

poly(l)lactide. AAPS PharmSciTech 2002; 3: E32.

57. Wehrle P, Magenheim B, Benita S. The influence of process parameters on the

PLA nanoparticle size distribution, evaluated by means of factorial design. Eur

J Pharm Biopharm 1995; 41:1926.

58. Nguyen XC, Herberger JD, Burke PA. Protein powders for encapsulation: A

comparison of spray-freeze drying and spray drying of darbepoetin alfa.

Pharm Res 2004; 21:50714.

59. Thomasin C, Merkle HP, Gander B. Drug microencapsulation by PLA/PLGA

coacervation in the light of thermodynamics. 1. Overview and theoretical

considerations. J Pharm Sci 1998; 87: 25968.

60. Thomasin C, Merkle HP, Gander B. Drug microencapsulation by PLA/PLGA

coacervation in the light of thermodynamics. Parameters determining

microsphere formation. J Pharm Sci 1998; 87: 26975.

61. Damge C, Michel C, Aprahamian M, and Couvreur P. New approach for oral

administration of insulin with polyalkylcyanoacrylate nanocapsules as drug

carrier, Diabetes 1988; 37: 246-51.

Bibliography


62. Alphandary PH, Aboubakar M, Jaillard D, Couvreur P, and Vauthier C.

Visualization of insulin-loaded nanocapsules: in-vitro and in-vivo studies after

oral administration to rats, Pharm Res 2003; 20: 1071-84.

63. McGhee JR, Mestecky JMT, Dertzbaugh JH, Eldridge M, Kiyono H. The

mucosal immune system: from fundamental concepts to vaccine development,

Vaccine1992; 10: 75-88.

64. Mestecky J and McGhee JR. Immunoglobulin A (IgA): molecular and cellular

interactions involved in IgA biosynthesis and immune response, Adv Immunol

1987; 40: 153-245.

65. Illum L, Jabbal-Gill I, Hinchcliffe M, Fisher AN, Davis SS. Chitosan as a

novel nasal delivery system for vaccines, Adv Drug Deliv Rev 2001; 51: 81-

96.

66. Regnstrom K, Ragnarsson EG, Koping-Hoggard M, Torstensson E, Nyblom

H, Artursson P. PEI - a potent, but not harmless, mucosal immuno-stimulator

of mixed Thelper cell response and FasL-mediated cell death in mice, Gene

Ther 2003; 10: 1575- 83.

67. Eldridge JH, Meulbroek JA, Staas JK, Tice TR, and Gilley RM. Vaccine

containing biodegradable microspheres specifically enter the gut-associated

lymphoid tissue following oral administration and induce a disseminated

mucosal immune response. Adv Exp Med Biol 1989; 251: 191-202.

68. Foster N, Hirst BH. Exploiting receptor biology for oral vaccination with

biodegradable particulates, Adv Drug Deliv Rev 2005; 57: 431-50.

69. Attarki K, Pecquet S, Fattal E, Trolle ES, Chachaty PC, Andremont A,

Protective immunity against Salmonella typhimurium elicited in mice by oral

Bibliography


vaccination with phosphorylcholine encapsulated in poly (DL-lactide-co-

glycolide) microspheres, Infect. Immun 1997; 65: 853-857.

70. Fattal ES. Pecquet PC, Andremont A. Biodegradable microparticles for the

mucosal delivery of antibacterial and dietary antigens, Int J Pharm 2002; 242:

15- 24.

71. Jones DH, McBride BWC, Thornton DTO, Robinson A, Farrar GH. Orally

administered microencapsulated Bordetella pertussis fimbriae protect mice

from B. pertussis respiratory infection, Infect Immun 1996; 64: 489-94.

72. Kofler NC, Ruedl C, Rieser GW, Wolf H. Oral immunization with poly- (D,L-

lactide-co-glycolide) and poly-(L-lactic acid) microspheres containing

pneumotropic bacterial antigens, Int Arch Allergy Immunol 1997; 113: 424-

31.

73. Attarki EK, Fattal S, Pecquet S, Trolle E, Chachaty PC, Andremont A.

Mucosal immunogenicity elicited in mice by oral vaccination with

phosphorylcholine encapsulated in poly (D,L-lactide-co-glycolide)

microspheres Vaccine 1998; 16: 685-91.

74. Jung T, Kamm W, Breitenbach A, Hungerer KD, Hundt E, Kissel T. Tetanus

toxoid loaded nanoparticles from sulfobutylated poly(vinyl alcohol)-graft

poly(lactide-coglycolide): evaluation of antibody response after oral and nasal

application in mice, Pharm Res 2001; 18: 352-60.

75. Hagan O. Cholera toxin B subunit (CTB) entrapped in microparticles shows

comparable immunogenicity to CTB mixed with whole cholera toxin

following oral immunization. Int J Pharm 1995; 119, 251-55.

Bibliography


76. Gutierro I, Hernandez RM, Igartua M, Gascon AR, Pedraz JL, Influence of

dose and immunization route on the serum Ig G antibody response to BSA

loaded PLGA microspheres, Vaccine 2002; 20: 2181-90.

77. Gutierro I, Hernandez RM, Igartua M, Gascon AR, Pedraz JL. Size dependent

immune response after subcutaneous, oral and intranasal administration of

BSA loaded nanospheres, Vaccine 2002; 21: 67-77.

78. De TK, Rodman DJ, Holm BA, Prasad PN, Bergey EJ. Brimonidine

formulation in polyacrylic acid nanoparticles for ophthalmic delivery. J

Microencapsul 2003; 20:361.

79. De TK, Hoffman AS. A reverse microemulsion polymerization method for

preparation of bioadhesive polyacrylic acid nanoparticles for mucosal drug

delivery: loading and release of timolol maleate. Artif Cells Blood Subst

Immobil Biotech 2001; 29:31.

80. De TK, Hoffman AS. An ophthalmic formulation of beta adrenoreceptor

antagonist, levobetaxolol, using polyacrylic acid nanoparticles as carriers,

loading and release studies. J Bioactive Compatible Polym 2001; 16:20.

81. Zimmer A, Chetoni P, Saettone M, Zerbe H, Kreuter J. Evaluation of

pilocarpine loaded albumin nanoparticles as controlled drug delivery systems

for the eye. II. Coadministration with bioadhesive and viscous polymers. J

Control Rel 1995; 33:31.

82. Gilding DK, Reed AM. Biodegradable polymers for use in surgery:

polyglycolic/poly lactic acid homo and copolymers. Polymers 1979; 20:1459.

83. Yamamoto H, Kuno Y, Sugimoto S, Takeuchi H, Kawashima Y. Surface

modified PLGA nanospheres with chitosan improved pulmonary delivery of

Bibliography


calcitonin by mucoadhesion and opening of the intercellular tight junctions. J

Control Rel 2005; 102:373.

84. Pahl A, Szelenyi I. Asthma therapy in the new millennium. Inflamm Res

2002; 51:273.

85. Contreras LG, Hickey AJ. Pharmaceutical and biotechnological aerosols for

cystic fibrosis in therapy. Adv Drug Deliv Rev 2002; 54:1491.

86. Sharma S, White D, Imondi AR, Placke ME, Vail DM, Kris MG.

Development of inhalational agents for oncological use. J Clin Oncol 2001;

19:1839.

87. Suarez S, OHara P, Kazantseva M, et al. Airways delivery of rifampicin

microparticles for the treatment of tuberculosis. J Antimicrob Chemother

2001; 48:431.

88. Zwissler B. Inhaled vasodilators. Anaesthesist 2002; 51:603.

89. Owens DR. New horizons-alternative routes for insulin therapy. Nat Rev Drug

Discov 2002; 1:529.

90. Zhang Q, Shen Z, Nagai T. Prolonged hypoglycemic effect of insulin loaded

polybutylcyanoacrylate nanoparticles after pulmonary administration to

normal rats. Int J Pharm 2001; 218:75.

91. Koziara JM, Lockman PR, Alen DD, Mumper RJ. In situ bloodbrain barrier

transport of nanoparticles. Pharm Res 2003; 20:1772.

92. Schroder U, Sommerfield P, Urlich S, Sable B. Nanoparticle technology for

delivery of drugs across the bloodbrain barrier. J Pharm Sci 1998; 78:1305.

93. Kreuter J. Influence of the surface properties on nanoparticle-mediated

transport of drugs to the brain. J Nanosci Nanotechnol 2004; 4: 484-8.

Bibliography


94. Vila A, Sanchez A, Tobio M, Calvo P, Alonso MJ. Design of biodegradable

particles for protein delivery. J Control Rel 2002; 78:15.

95. Bilati U, Allemann E, Doelker E. Development of a nanoprecipitation method

intended for the entrapment of hydrophilic drugs into nanoparticles. Eur J

Pharm 2005; 24:67.

96. Sahoo SK, Ma W, Labhasetwar V. Efficacy of transferring conjugated

paclitaxel loaded nanoparticles in a murine model of prostate cancer. Int J

Cancer 2004; 112:335.

97. Fifis T, Gamvrellis A, Crimeen-irwin B, et al. Size dependent

immunogenicity: therapeutic and protective properties of nano vaccines

against tumors. J Immunol 2004; 173:3148.

98. Chen JH, Wang L, Ling R, et al. Body distribution of nanoparticles containing

adriamycin injected into the hepatic artery of hepatoma bearing mice. Dig Dis

Sci 2004; 49:1170.

99. Gao H, Wang JY, Shen XZ, Deng YH, Zhang W. Preparation of magnetic

polybutylcyanoacrylate nanospheres encapsulated with aclacinomycin A and

its effect on gastric tumor. World J Gastroenterol 2004; 10:2010.

100. ONeal DP, Hirsch LR, Halas NJ, Payne JD, West JL. Photo thermal tumor

ablation in mice using near infra red absorbing nanoparticles. Cancer Lett

2004; 23:2406.

101. Santhakumaran LM, Thomas T, Thomas TJ. Enhanced cellular uptake of a

triplex- forming oligonucleotides by nanoparticles formation in the presence

of polypropylenimine dendrimers. Nucleic Acid Res 2004; 15:2102.

Bibliography


102. Kumar CS, Leuschner C, Doomes EE, Henry L, Juban M, Hormes J. Efficacy

of lytic peptide bound magnetite nanoparticles in destroying breast cancer

cells. J Nanosci Nanotechnol 2004; 4:245.

103. Roy I, Ohulchanskyy TY, Pudavar HE, et al. Ceramic based nanoparticles

entrapping water soluble photosensitizing anticancer drugs a novel drug

carrier system for photodynamic therapy. J Am Chem Soc 2003; 125:7860.

104. Chawla JS, Amiji MM. Cellular uptake and concentrations of tamoxifen upon

administration in poly(epsilon-caprolactone) nanoparticles. AAPS Pharm

SciTech 2003; 5: E3.

105. Panyam J, Zhou WZ, Prabha S, Sahoo SK, Labhasetwar V. Rapid endo-

lysosomal escape of poly (DL-lactide-co-glycolide) nanoparticles:

implications for drug and gene delivery. Fase J 2002; 16: 1217-26.

106. Hedley M, Curley J, Urban R. Microspheres containing plasmid-encoded

antigens elicit cytotoxic T-cell responses. Nat Med 1998; 4: 365-368.

107. Pecora R. Dynamic light scattering measurement of nanometer particles in

liquids. J Nanoparticle Res 2000; 2:123131.

108. Chu B, Liu T. Characterization of nanoparticles by scattering techniques. J

Nanoparticle Res 2000; 2:2941.

109. Kerker M. The scattering of light and other electromagnetic radiation. New

York: Academic Press, 1969.

110. McClements DJ. Principles of ultrasonic droplet size determination in

emulsions. Langmiur 1996; 12: 34543461.

111. Dukhin AS, Goetz PJ. Characterization of aggregation phenomena by means

of acoustic and electroacoustic spectroscopy. Colloids Surf A: Physicochem

Eng Aspects 1998; 144:4958.

Bibliography


112. Westesen K, Bunjes H, Koch MHJ. Physicochemical characterization of lipid

nanoparticles and evaluation of their drug loading capacity and sustained

release potential. J Control Rel 1997; 48:223236.

113. Lieberman A. Particle characterization in liquids. In: Knapp JZ, Barber TA,

Lieberman A, eds. Liquid- and Surface-Borne Particle Measurement

Handbook. New York: Marcel-Dekker, 1996:128.

114. Bunjes H, Westesen K, Koch MHJ. Crystallization tendency and polymorphic

transitions in triglyceride nanoparticles. Int J Pharm 1996; 129:159173.

115. Jores K, Mehnert W, Drechsler M, Bunjes H, Johann C, Maeder K.

Investigations on the structure of solid lipid nanoparticles (SLN) and oil-

loaded solid lipid nanoparticles by photon correlation spectroscopy, field-flow

fractionation and transmission electron microscopy. J Control Rel 2004;

95:217227.

116. Chorny M, Fishbein I, Danenberg HD, Golomb G. Study of the drug release

mechanism from tyrphostin AG-1295-loaded nanospheres by in situ and

external sink methods. J Control Rel 2002; 83:401414.

117. Tobio M, Gref R, Sanchez A, Langer R, Alonso MJ. Stealth PLA-PEG

nanoparticles as protein carriers for nasal administration. Pharm Res 1998;

15:270275.

118. Calvo P, Vila-Jato JL, Alonso MJ. Comparative in vitro evaluation of several

colloidal systems, nanoparticles, nanocapsules, and nanoemulsions, as ocular

drug carriers. J Pharm Sci 1996; 85:530536.

119. zur Mu¨ hlen A, zur Mu¨ hlen E, Niehus H, Mehnert W. Atomic force

microscopy studies of solid lipid nanoparticles. Pharm Res 1996; 13:1411

1416.

Bibliography


120. Shi HG, Farber L, Michaels JN, et al. Characterization of crystalline drug

nanoparticles using atomic force microscopy and complementary techniques.

Pharm Res 2003; 20:479484.

121. Montasser I, Fess H, Coleman AW. Atomic force microscopy imaging of

novel type of polymeric colloidal nanostructures. Eur J Pharma Biopharm,

2002; 54:281284.

122. Muller RH. Hydrophobic interaction chromatography (HIC) for determination

of the surface hydrophobicity of particulates. In: Particle and Surface

Characterization Methods, Based on the Invited Lectures presented at the

Colloidal Drug Carriers Expert Meeting, 2nd, Mainz, Mar. 6, 1997. Mu¨ ller

RH, Mehnert W, Hildebrand GE, eds. 1997.

123. Tobio M, Gref R, Sanchez A, Langer R, Alonso MJ. Stealth PLA-PEG

nanoparticles as protein carriers for nasal administration. Pharm Res 1998; 15:

270275.

124. Mosqueira VCF, Legrand P, Gulik A et al. Relationship between complement

activation, cellular uptake and surface physicochemical aspects of novel PEG-

modified nanocapsules. Biomaterials 2001; 22: 29672979.

125. Vauthier C, Schmidt C, Couvreur P. Measurement of the density of polymeric

nanoparticulate drug carriers by isopycnic centrifugation. J Nanoparticle Res

1999; 1: 411418.

126. Hunter RJ, ed. Colloid Science: Zeta Potential in Colloid Science: Principles

and Applications. London: Academic Press, 1981.

127. Yang SC, Zhu JB. Preparation and characterization of camptothecin solid lipid

nanoparticles. Drug Dev Ind Pharm 2002; 28:265274.

Bibliography


128. Lacoulonche F, Gamisans F, Chauvet A, Garcia ML, Espina M, Egea MA.

Stability and in vitro drug release of flurbiprofen loaded poly (e-caprolactone)

nanospheres. Drug Dev Ind Pharm 1999; 25:983993.

129. Cavalli R, Caputo O, Carlotti E, Trotta M, Scarnecchia C, Gasco MR.

Sterilization and freeze-drying of drug-free and drug-loaded solid lipid

nanoparticles. Int J Pharm 1997; 148:4754.

130. Neutra MR, Kozlowski PA. Mucosal vaccines: the promise and the challenge.

Nat. Rev. Immunol 2006; 6: 148-158.

131. Nagy B, Fekete PZ. Enterotoxigenic Escherichia coli (ETEC) in farm animals.

Vet Res 1999; 30: 259-84.

132. Fairbrother JM, Nadeau E, Gyles CL. Escherichia coli in post weaning

diarrhea in pigs: an update on bacterial types, pathogenesis, and prevention

strategies. Anim Health Res Rev 2005: 6; 17-39.

133. Nataro JP, Kaper JB. Diarrheagenic Escherichia coli. Clin Microbiol Rev

1998: 11; 142-201.

134. Gill DM, Richardson SH. Adenosine diphosphate-ribosylation of adenylate

cyclase catalyzed by heat-labile enterotoxin of Escherichia coli: comparison

with cholera toxin. J Infect Dis 1980; 141:6470.

135. Holmgren J. Actions of cholera toxin and the prevention and treatment of

cholera. Nature 1981; 292: 413417.

136. Rao MC. Toxins which activate guanylate cyclase: heat-stable enterotoxins.

Ciba Found Symp 1985; 112:7493.

137. Sears CL, Kaper JB. Enteric bacterial toxins: mechanisms of action and

linkage to intestinal secretion. Microbiol Rev 1996; 60: 167-215.

138. David L, Woude MVD. Fimbriae. ASM PRESS, Washington, DC, 1996.

Bibliography


139. Mol O, Visschers RW, de Graaf FK, Oudega B. Escherichia coli periplasmic

chaperone FaeE is a homodimer and the chaperone-K88 subunit complex is a

heterotrimer. Mol Microbiol 1994; 11: 391-402.

140. Nishibuchi M, Fasano A, Russell RG, Kaper JB. Enterotoxigenicity of Vibrio

parahaemolyticus with and without genes encoding thermostable direct

hemolysin. Infect Immun 1992; 60:35393545.

141. Argenzio RA, Liacos JA, Levy ML, Meuten DJ, Leece JG, Powell DW.

Villous atrophy, crypt hyperplasia, cellular infiltration, and impaired glucose-

Na absorption in enteric cryptosporidiosis of pigs. Gastroenterology 1990;

98:11291140.

142. Weikel CS, Sando J, Guerrant RL. Stimulation of porcine jejunal ion secretion

in vivo by protein kinase-c activators. J Clin Invest 1985; 76:24302435.

143. Delor I, Cornelis GR. Role of Yersinia enterocolitica Yst toxin in

experimental infection in young rabbits. Infect Immun 1992; 60:42694277.

144. Spira WM, Sack RB, Froehlich JL. Simple adult rabbit model for Vibrio

cholerae and enterotoxigenic Escherichia coli diarrhea. Infect Immun 1981;

32:739747.

145. Sack RB, Kline RL, Spira WM. Oral immunization of rabbits with

enterotoxigenic Escherichia coli protects against intraintestinal challenge.

Infect Immun 1988; 56:387394.

146. Pierce NF, Kaper JB, Mekalanos JJ, Cray WC, Richardson K. Determinants of

the immunogenicity of live virulent and mutant Vibrio cholerae O1 in rabbit

intestine. Infect Immun 1987; 55:477481.

Bibliography


147. Ussing HH, Zerahn K. Active transport of sodium as the source of electric

current in the short-circuited isolated frog skin. Acta Physiol Scand 1951;

23:110127.

148. Guerrant RL, Brunton LL, SchnaitmanTC, Rebhun LI, Gilman AG. Cyclic

adenosine monophosphate and alteration of Chinese hamster ovary cell

morphology: a rapid, sensitive in vitro assay for the enterotoxins of Vibrio

cholerae and Escherichia coli. Infect Immun 1974; 10:320 327.

149. Donta ST, Moon HW, Whipp SC. Detection of heat-labile Escherichia coli

enterotoxin with the use of adrenal cells in tissue culture. Science 1974;

183:334336.

150. Chapman PA, Daly CM. Evaluation of non-radioactive trivalent DNA probe

(LT, ST1a, ST1b) for detecting enterotoxigenic Escherichia coli. J Clin Pathol

1993; 46:309312.

151. Scotland SM, Flomen RH, Rowe B. Evaluation of a reversed passive latex

agglutination test for detection of Escherichia coli heat-labile toxin in culture

supernatants. J Clin Microbiol 1989; 27:339340.

152. Honda T, Akhtar Q, Glass RI, Kibriya AK. A simple assay to detect

Escherichia coli producing heat labile enterotoxin: results of a field study of

the Biken tests in Bangladesh. Lancet 1981; 609610.

153. Svennerholm AM, Holmgren J. Identification of Escherichia coli heat-labile

enterotoxin by means of a ganglioside immunosorbent assay (GM1-ELISA)

procedure. Curr Microbiol 1978; 1:1923.

154. Svennerholm AM, Wiklund G. Rapid GM1-enzyme-linked immunosorbent

assay with visual reading for identification of Escherichia coli heat-labile

enterotoxin. J Clin Microbiol 1983; 17:596600.

Bibliography


155. Svennerholm AM, Wikstrom M, Lindblad M, Holmgren J. Monoclonal

antibodies against Escherichia coli heat-stable toxin (STa) and their use in a

diagnostic ST ganglioside GM1-enzyme-linked immunosorbent assay. J Clin

Microbiol 1986; 24:585590.

156. Subekti DS, Lesmana P, Tjaniadi P, Machpud N, Sukarma S, Daniel JC et al.,

Prevalence of Enterotoxigenic Escherichia coli (ETEC) in hospitalized acute

diarrhea patients. Diagn Microbiol Infect Dis 2003; 47(2): 399-405.

157. Nicklasson M, Sjoling A, Wiklund G, Svennerholm AM. Molecular genetics

of bacteria and phages, p. 135. Cold Spring Harbor Laboratory, Cold Spring

Harbor, NY.

158. Ericsson CD. Travellers diarrhoea. Int. J. Antimicrob. Agents 2004; 21:116

124.

159. Ericsson CD, DuPont HL, Mathewson JJ. Single dose ofloxacin plus

loperamide compared with single dose or three days of ofloxacin in the

treatment of travelers diarrhea. J Travel Med 1997; 4:37

160. DuPont HL, Jiang ZD, Ericsson CD, Adachi JA, Mathewson JJ, DuPont MW

et al., Rifaximin versus ciprofloxacin for the treatment of travelers diarrhea:

a randomized, double-blind clinical trial. Clin Infect Dis 2001; 33:18071815.

161. Cravioto A, Reyes RE, Trujillo F, Uribe F, Navarro J et al., Risk of diarrhea

during the first year of life associated with initial and subsequent colonization

by specific enteropathogens. Am J Epidemiol 1990; 131:886904.

162. Levine MM, Svennerholm AM. Enteric vaccines: present and future, 2nd ed.

BC Decker, New York, NY, 2001.

Bibliography


163. Guerena-Burgueno F, Hall ER, Taylor DN, Cassels FJ, Scott DA et al., Safety

and immunogenicity of a prototype enterotoxigenic Escherichia coli vaccine

administered transcutaneously. Infect Immun 2002; 70:18741880.

164. Svennerholm AM, Ahren C, Jertborn M. 1997. Oral inactivated vaccines

against enterotoxigenic Escherichia coli, ed. II. Marcel Dekker Inc, New York,

NY.

165. Levine MM. Modern vaccines. Enteric infections. Lancet 1990; 335:958 961.

166. Sher P, Insavle G, Porathnam S, Pawar AP. Low Density porous carrier drug

adsorption and release study by response surface methodology using different

solvents. Int J Pharm 2007; 331: 72-83.

167. Shivanand P, Sprockel OL. A controlled porosity drug delivery system. Int J

Pharm 1998; 167: 83-96.

168. Sharma S, Sher P, Badve S, Atmaram PP. Adsorption of Meloxicam on porous

calcium silicate: Characterisation and tablet formulation. AAPS Pharm Sci

Tech 2005; 6: E618-25.

169. Streubel A, Sipemann J, Bodmeier R. Floating matrix tablets based on low

density foam powder: Effects of formulation and processing parameters on

drug release. Eur J Pharm Sci 2003; 18: 37-45.

170. Yuasa H, Takashima Y, Kanaya Y. Studies on the development of intragastric

floating and sustained release preparation: I: Application of calcium silicate as

a floating carrier. Chem Pharm Bull (Tokyo) 1996; 44: 1361-6.

171. Strebuel A, Siepmann J, Bodmeier R. Floating microparticles based on low

density foam powder. Int J Pharm 2002; 241: 279-92.

Bibliography


172. Salis A, Sanjust E, Solinas V, Monduzzi M. Characterization of Accurel MP

1004 polypropylene powder and its use as a support for lipase immobilization.

J Mol Cat B Enz 2003; 24-25: 75-82.

173. Byrne RS, Deasy PB. Use of commercial porous ceramic particles for

sustained drug delivery. Int J Pharm 2002; 246: 61-73.

174. Song SW, Hidajat K, Kawi S. Functionalized SAB-15 material as carrier from

controlled drug delivery: Infl uence of surface properties on matrix drug

interactions. Langmuir 2005; 21: 9568-75.

175. Andersson J, Rosenhoim J, Areva S, Linden M. Influences of material

characteristics on ibuprofen drug loading and release profiles from ordered

micro- and mesoporous silica matrices. Chem Mater 2004; 16: 4160-7.

176. Gren T, Bjerre C, Camber O, Ragnarsson G. In vitro drug release from porous

cellulose matrices. Int J Pharm 1996; 141: 53-62.

177. Charney C, Begu S, Tourne P, Nicole L, Lerner D, Devoisselle JM. Inclusion

of ibuprofen in mesoporous template silica: Drug loading and release property.

Eur J Pharm Biopharm 2003; 57: 533-40.

178. Wendorf J, Singh M, Chesko J, Kazzaz J, Soewanan E, Ugozzoli M. A

Practical Approach to the use of Nanoparticles for Vaccine Delivery. J Pharm

Sci 2006: 95; 12-13.

179. Borges O, Borchard G, Verhoef C. Preparation of coated nanoparticles for a

new mucosal vaccine delivery system. Int J Pharm 2005: 299; 155-166.

180. Rieux A, Fievez V, Garinot M. Nanoparticles as potential oral delivery

systems of proteins and vaccines: a mechanistic approach. J Control Rel 2005,

55; 177-181.

Bibliography


181. Arayne MS, Sultana N. Porous nanoparticles in drug delivery systems. Pak J

Pharm Sci 2006; 19(2): 155-158.

182. Huyghebaert V, Snoeck V, Vermeire A, Cox E, Goddeeris BM, Remon JP.

Development of an enteric-coated pellet formulation of F4 fimbriae for oral

vaccination of suckling piglets against enterotoxigenic Escherichia coli

infections. Eur J Pharm Biopharm 2005; 59: 273281.

183. Broecka WV, Cox E, Goddeeris B. Receptor-specific binding of purified F4 to

isolated villi. Vet Microbiol 1999; 68: 255-263.

184. Verdonck V, Hauwere V, Bouckaert J, Goddeeris BM, Cox E. Fimbriae of

enterotoxigenic Escherichia coli function as a mucosal carrier for a coupled

heterologous antigen. Journal of Control Rel 2005; 104: 243258.

185. Broeck WV, Cox E, Goddeeris BM. Induction of immune responses in pigs

following oral administration of purified F4 Fimbriae. Vaccine 1999; 17:

2020-2029.

186. Verdonck F, Joensuu JJ, Stuyven E, Meyer JD, Muilu M. The polymeric

stability of the Escherichia coli F4 (K88) fimbriae enhances its mucosal

immunogenicity following oral immunization. Vaccine 2008: 26; 57285735.

187. Murillo M, Gamazo C, Goñi MM, Irache JM. Development of microparticles

prepared by spray-drying as a vaccine delivery system against brucellosis. Int

J Pharm 2002: 242; 241-244.

188. Nicholas HW, Daniel G. Anderson, Steven R. Little, Michael S. von Berwelt-

Baildon. pH - triggered microparticles for peptide vaccination. J of Immune

2004: 173; 2578-2585.

Bibliography


189. Benoit B, Marie AB, Loc D, Odile P. Single-Dose Mucosal Immunization

with Biodegradable Microparticles Containing a Schistosoma mansoni

Antigen. Infect and Immun 1999, 26432648.

190. Gregory M. Glenn, Artur P. Klamczynski, Delilah Wood, William Ort Starch-

based Porous Microparticles: Properties and Applications. USDA, ARS,

Western Regional Research Center, 800 Buchanan St., Albany, CA 94710

USA

191. Gupta V, Nahar K, Ahsan F. Prostaglandin E1 (PGE1) Encapsulated Large

Porous Microparticles An Approach for Sustained Pulmonary Vasodilation.

AAPS PharmaSciTech 2006: 5: 217-23

192. Sunil K. Jain, Govind PA, Narendra KJ. Evaluation of Porous Carrier-based

Floating Orlistat Microspheres for Gastric Delivery. AAPS PharmSciTech

2006; 7 (4):224-32

193. Luo Gu, Ji-Ho Park, Kim H. Duong, Erkki Ruoslahti, Michael J. Sailor

magnetic luminescent porous silicon microparticles for localized delivery of

molecular drug payloads. Small 2010, 17.

194. Amit R, Quamrul H. Majumder and Fakhrul Ahsan. Inhalable Large porous

microspheres of low molecular weight heparin: in vitro and in vivo evaluation.

J Control Rel 2008; 128(3): 224232.

195. Vivek G, Fakhrul A. Influence of PEI as a core modifying agent on PLGA

microspheres of PGE1, A pulmonary selective vasodilator, Int J Pharm 2011;

413(1-2): 5162.

196. Olga B, Gerrit B, Verhoef JC, Adriano S, Hans EJ. Preparation of coated

nanoparticles for a new mucosal vaccine delivery system. Int J Pharm 2005;

299: 155166.

Bibliography


197. Janet W, Manmohan S, James C, Jina K, Elawati S, Mildred Ugozzoli, Derek

OH. A practical approach to the use of nanoparticles for vaccine delivery. JPS

2006; 95(12): 27382750.

198. Seung YK, Sajan G, Volker B, Rodney M, David F, Radhey SK. Porcine

intestinal epithelial cell lines as a new in vitro model for studying adherence

and pathogenesis of enterotoxigenic Escherichia coli. Vet Microbiol 2008;

130: 191197.

199. Harley WM, Thom OB. Vaccines for preventing Enterotoxigenic Escherichia

coli infections in farm animals. Vaccine 1993, 11(2); 213-219.

200. Yuhua Li, Xiaotian Qiu, Hejun Li, Qin Zhang. Adhesive patterns of

escherichia coli f4 in piglets of three breeds, J of Genetics and Genomics

2007, 34(7): 591-599.

201. Frank V, Jussi JJ, Edith S, Julie DM, Mikko M, Minna P, Bruno MG, Jan M.

The polymeric stability of the Escherichia coli F4 (K88) fimbriae enhances its

mucosal immunogenicity following oral immunization. Vaccine 2008; 26:

57285735.

202. Snoeck V, Verfaillie T, Verdonck F, Goddeeris BM, Cox E. The jejunal

Peyers patches are the major inductive sites of the F4-specific immune

response following intestinal immunisation of pigs with F4 (K88) fimbriae.

Vaccine 2006; 24: 38123820.

203. Fairbrother JM, Nadeau E, Gyles CL. Escherichia coli in postweaning

diarrhea in pigs: an update on bacterial types, pathogenesis, and prevention

strategies. Anim Health Res Rev 2005; 6, 17-39.

Bibliography


204. Deprez P, Van DH, Muylle E, Oyaert W. The influence of the administration

of sows milk on the postweaning excretion of hemolytic Escherichia coli in

piglets. Vet Res Commun 1986; 10: 469-478.

205. Rasschaert K, Verdonck F, Goddeeris BM, Duchateau L. Cox E. Screening of

pigs resistant to F4 enterotoxigenic Escherichia coli (ETEC) infection. Vet

Microbiol 2007; 123: 249-253.

206. Verdonck F, Snoeck V, Goddeeris BM, Cox E. Binding of a monoclonal

antibody positively correlates with bioactivity of the F4 fimbrial adhesion

FaeG associated with post-weaning diarrhea in piglets. J Immunol Methods

2004; 294: 81-88.

207. Van den Broeck, Cox E, Goddeeris BM. Induction of immune responses in

pigs following oral administration of purified F4 fimbriae. Vaccine 1999a; 17:

2020-2029.

208. Van den Broeck W, Cox E, Goddeeris BM. Receptor-dependent immune

responses in pigs after oral immunization with F4 fimbriae. Infect Immun

1999b; 67, 520- 526.

209. Rasschaert K, Verdonck F, Goddeeris BM, Duchateau L, Cox E, Screening of

pigs resistant to F4 enterotoxigenic Escherichia coli (ETEC) infection. Vet

Microbiol 2007; 123: 249253.

210. Devriendt B, Stuyven E, Verdonck F, Goddeeris BM, Cox E. Enterotoxigenic

Escherichia coli (K88) induce proinflammatory responses in porcine intestinal

epithelial cells. Dev Comp Immunol 2010; 34(11):1175-82.

211. Verdonck F, Cox E, van Gog K, Van der Stede Y, Duchateau L, et al.,

Different kinetic of antibody responses following infection of newly weaned

Bibliography


pigs with an F4 enterotoxigenic Escherichia coli strain or an F18

verotoxigenic Escherichia coli strain, Vaccine 2002; 20: 29953004.

212. Verdonck F, Cox E, Van der Stede Y, Goddeeris BM. Oral immunization of

piglets with recombinant F4 fimbrial adhesin FaeG monomers induces a

mucosal and systemic F4-specific immune response, Vaccine 2004; 22: 4291

4299.

213. Kristien R, Bert D, Herman F, Bruno MG, Eric C. Clathrin mediated

endocytosis and transcytosis of Enterotoxigenic Escherichia coli F4 fimbriae

in porcine intestinal epithelial cells, Vet Immun and Immunopath 2010; 137:

243250.

214. Indian Pharmacopoeia. Government of India, Ministry of Health & Family

Welfare, Published by Indian Pharmacoepial commission, Ghazaibad, 2007;

4.1:1133.

215. Trevor M.S, Nicholas H, Averys drug treatment 4th Edition: 1655.

216. Harry GB. Analytical profiles of drug substances and excipients. Academic

press, San Diego, California: Elsevier publication; 1994.

217. Wade A, Weller PJ, Handbook of Pharmaceutical Excipients. 2nd edition,

Asmercial Pharmaceutical Association, Washington D.C. and Royal

Pharmaceutical Press, 1999; 362-366.

218. James W.Mc Ginity, Aqueous polymeric coating for pharmaceutical dosage

forms. 2nd edition, 197-198.

219. Dowe CR, Sheskey PJ. Handbook of Pharmaceutical excipient. 5th ed.

Pharmaceutical press. 2006.

220. Chudzikowski R. Polyvinyl alcohol. Manuf Chem Aerosol News 1970; 41(7):

3137.

Bibliography


221. Finch CA, ed. Polyvinyl Alcohol Developments. Chichester: Wiley, 1992.

222. Suh H, Jun HW. Physicochemical and release studies of naproxen in

poloxamer gels. Int J Pharm 1996; 129: 1320.

223. Pandit NK, Wang D. Salt effects on the diffusion and release rate of

propranolol from poloxamer 407 gels. Int J Pharm 1998; 167: 183189.

224. http://en.wikipedia.org/wiki/Ammonium_carbonate

225. http://www.atcc.org/ATCCAdvancedCatalogSearch/ProductDetails/tabid/452/

Default.aspx?ATCCNum=35401&Template=bacteria.

226. Food and Drug Administration (FDA), Guidelines for Industry in

Bioanalytical Method Validation, Rockville, MD, USA, 2001.

227. Ibrahim AA, Mohammed NA. Validated liquid chromatographic

determination of 5-fluorouracil in human plasma. J of Chromat 2004; 804:

435-439.

228. Balmuralidhara V, Pramod TM, Vishal GN, Moin A, Gangadharappa HV.

Development of pH sensitive microspheres of esomeprazole magnesium using

natural gums for zollinger ellison syndrome. Drug Deliv Lett 2012; 2: 108-

117.

229. Nisha MJ, Pramod KS. Cross-linked nanoparticles of cytarabine:

encapsulation, storage and in-vitro release, African J of Pharmacy and

Pharmacol 2007; 1: 10-13.

230. Lachman LH. Lieberman JL. The Theory and Practice of Industrial

Pharmacy. Philadelphia, PA: Lea and Febiger 1987; 317-318.

231. Olga Borges et al., Preparation of coated nanoparticles for a new mucosal

vaccine delivery system. Int J Pharm 2005, 299, 155166.

http://en.wikipedia.org/wiki/Ammonium_carbonatehttp://www.atcc.org/ATCCAdvancedCatalogSearch/ProductDetails/tabid/452/

Bibliography


232. Paulo C, Jose Manuel SL. Modeling and compaction of dissolution profiles.

Eur J of Pharma Sci 2001; 13: 123-33.

233. Korsmeyer RW, Gurny R, Doelker EM, Buri P, Peppas NA. Mechanism of

solute release from porous hydrophilic polymers. Int J Pharm 1983; 15: 25-35.

234. Crank J. Diffusion in a plane sheet. In: The Mathematics of Diffusion, 2nd

Edition. Oxford University Press, Oxford, 1975; 47-49.

235. Higuchi T. Mechanism of sustained-action medication. Theoretical analysis of

rate of release of solid drugs dispersed in solid matrices. J Pharm Sci 1963; 52:

1145-49.

236. Jacobs AAC, Graaf FK. Production of K88, K99 and F41 fibrillae in relation

to growth phase, and a rapid procedure for adhesion purification. FEMS

Microbiol Lett 1985; 26:1519.

237. Weber K, Osborn M. The reliability of molecular weight determinations by

dodecyl sulfate polyacrylamide gel electrophoresis. J Biol Chem 1969; 244:

4406-4412.

238. Erickson AK, Willgohs JA, McFarland SY, Benfield DA, Francis DH.

Identification of two porcine brush border glycoproteins that bind the K88ac

adhesin of Escherichia coli and correlation of these glycoproteins with the

adhesive phenotype. Infect Immun 1992; 60: 983-988.

239. Snoeck V, Cox E, Verdonck F, Joensuu JJ, Goddeeris BM. Influence of pH

and gastric digestion on antigenicity of F4 fimbriae for oral immunisations.

Vet Microbiol 2004; 98(1), 45-53.

240. Sofia P, Bikiaris D, Konstantinos A, Evangelos K, Manolis G. Chitosan

nanoparticles loaded with dorzolamide and pramipexole. Carbohydrate

Polymers 2008; 73: 4454.

Bibliography


241. Snoeck V, Cox E, Verdonck F, Joensuu JJ, Goddeeris BM. Influence of pH

and gastric digestion on antigenicity of F4 fimbriae for oral immunisations.

Vet Microbiol 2004; 98(1): 45-53.

242. Wim VDB, Eric C, Bruno MG. Receptor-Dependent Immune Responses in

Pigs after Oral Immunization with F4 Fimbriae. Infect and Immun 1999; 520

526.

243. Zohreh M, Farid AD, Saman H, Tina Amini et al., Stability studies of

chitosan-DNA-FAP-B nanoparticles for gene delivery to lung epithelial cells,

Acta Pharm 62 (2012) 8392.

244. Gowda DV, Mohammed S. Khan, Sathiraju V. Development and evaluation of

phosphated cross-linked guar gum microspheres for improved delivery of

anticancer drug to colon, Polymer-Plastics Tech and Eng 2012; 51: 1395

1402.

245. Hasegawa M, Sudo A, Komlev VS, Barinov SM, Uchida A. High release of

antibiotic from a novel hydroxyapatite with bimodal pore size distribution. J

Biomed Mater Res Part B: Appl Biomater 2003; 70: 332-339.

246. Sivakumar M, Rao KP. Preparation, characterization and in vitro release of

gentamicin from coralline hydroxyapatite-gelatin composite microspheres.

Biomaterials 2002; 23: 3175-3181.

247. Burgos AE, Belchior JC, Sinisterra RD. Controlled release of rhodium (II)

carboxylates and their association complexes with cyclodextrins from

hydroxyapatite matrix. Biomaterials 2002; 23: 2519-2526.

248. Itokazu M, Esaki M, K. Yamamoto, T. Tanemori and T. Kasai. Local drug

delivery system using ceramics: vacuum method for impregnating a

Bibliography


chemotherapeutic agent into a porous hydroxyapatite block. J Mat Sci: Mat

Med 1999; 10: 249-252.

249. Lebugle AR, Bonnevialle P, Voigt JJ, Canal P, Rodriguez F. Study of

implantable calcium phosphate systems for the slow release of methotrexate.

Biomaterials 2002; 23: 3517-3522.

250. Arm DM, Tencer AF, Bain SD, Celino D. Effect of controlled release of

platelet-derived growth factor from a porous hydroxyapatite implant on bone

in growth. Biomaterials 1996; 17: 703-709.

251. Healy AM, McDOnald BF, Tajber L, Corrigan OI. Characterisation of

excipient-free nanoporous microparticles (NPMPs) of bendroflumethazide.

Eur J Pharm and Biopharm 2008; 69: 1182-1186.

252. Narendra C, Srinath MS, Ganesh B. Optimization of Bilayer Floating Tablet

Containing Metoprolol Tartrate as a Model Drug for Gastric Retention. AAPS

Pharm. Sci Tech 2006; 7: 45-50.

253. Hoffman BB. Catecholamines, sympathomimetics drugs, and adrenergic

receptor antagonists. In: Hardman JG, Limbird LE eds. Goodman and

Gilmans The Pharmacological Basis of Therapeutics. 10th ed. New York,

NY: McGraw-Hill, 2001, 255-6.

254. Jobin G, Cortot A, Godbillon J. Investigation of drug absorption from the

gastrointestinal tract of man, I: Metoprolol in stomach, duodenum, and

jejunum. Br J Clin Pharmacol 1985; 19: 975-9.

255. Tarara Te et al. Methods of spray drying pharmaceutical compositions, US

Patent, 2003; 6: 565,885.

256. Barnes GT and Gentle IR. Interfacial Scinece. New York, Oxford Univeristy

Press Inc. 2005.

Bibliography


257. Mohammed S. Khan, Gowda D. Vishakante, Afifa B. Preparation and

evaluation of sodium alginate porous dosage form as carriers for low dosed

active pharmaceutical ingredient, Turk J Pharm Sci 2012; 9(2): 183-198.

258. Nidhin M, Indumathy R, Sreeram KJ, Balachandran UN. Synthesis of iron

oxide nanoparticles of narrow size distribution on polysaccharide templates.

Bull Mater Sci 2008; 31(1): 9396.

259. Akansha T, Ranjana G, Shubhini A. PLGA Nanoparticles of Anti Tubercular

Drug: Drug Loading and Release Studies of a Water In-Soluble Drug. Int J of

Pharm Tech Res 2010; 2: 2116-2123.

260. Betül AY, Jean PB, Alf L. Paclitaxel-Loaded Lipid Nanoparticles Prepared by

Solvent Injection or Ultrasound Emulsification. Drug Dev Ind Pharm 2006;

32: 10891094.

261. Vijaya Baskar G, N Narayanan, Rajiv G, Samad A. Formulation and

Evaluation of Gastro-retentive Floating Multi-particulate System of

Metoprolol Tartarate, Trop J of Pharm Res 2010; 9 (2): 181-186

262. Esra B, Taner S. A design and evaluation of layered matrix tablet formulations

of metoprolol tartrate. AAPS PharmSciTech 2010; 11(2): 563-73.

263. Kosek M, Bern C, Guerrant RL. The global burden of diarrhoeal disease, as

estimated from studies published between 1992 and 2000. Bull. W.H.O. 2003;

81:197204.

264. Nataro JP, Kaper JB. Diarrheagenic Escherichia coli. Clin Microbiol Rev

1998; 11: 142201.

265. World Health Organization. New frontiers in the development of vaccines

against enterotoxigenic (ETEC) and enterohaemorrhagic (EHEC) E. coli

infections. Weekly Epidemiol Rec 13: 98100, (1999).

Bibliography


266. DebRoy C, Maddox CW. Identification of virulence attributes of

gastrointestinal Escherichia coli isolates of veterinary significance. Anim

Health Res Rev 2001; 1(2): 129-140.

267. Rutter JM, Jones GM. Protection against enteric disease caused by Escherichia

colia model for vaccination with a virulence determinant? Nature 1973;

242: 531532.

268. Jeffrey O, Sham H. Formulation and characterization of spray-dried powders

containing nanoparticles for aerosol delivery to the lung. Int J Pharm 2004;

268(2): 457-467.

269. Scheila RS, Adriana R, Pohlmann GM, Sílvia SG. Development of

nanocapsule suspensions and nanocapsule spray-dried powders containing

melatonin. J Braz Chem Soc 2006; 17 (3).

270. Adriana RP, Valeria W, Omar M, Nádya PS. Spray-dried indomethacin-

loaded polyester nanocapsules and nanospheres: development, stability

evaluation and nanostructure models. Eur J Pharm Sci 2002; 16 (4-5): 305-31.

271. Zambaux MF, Bonneaux F, Gref R, Maincent P, Dellacherie E, Alonso MJ et

al., Influence of experimental parameters on the characteristics of poly (lactic

acid) nanoparticles prepared by a double emulsion method. J of Control Rel

1998; 50: 3140

272. Gilles P, Marie-Jeanne M, Assia D, Carlo D, Dominique D. Mucoadhesion of

colloidal particulate systems in the gastro-intestinal tract. Eur J of Pharma and

Biopharm 1997; 44: 25-31

273. Andreas B, Andrea W, Karin A, Alexander G. Thiomers: Preparation and in

vitro evaluation of a mucoadhesive nanoparticulate drug delivery system. Int J

of Pharm 2006; 317: 7681.

Bibliography


274. Anitha RD, Shantha LK. Bioadhesive chitosan nanoparticles: Preparation and

characterization. Carbohydrate Polymers 2010; 81: 243251

275. Laila Fatima AA, Sajeev C. Multiparticulate Formulation Approach to Colon

Specific Drug Delivery: Current Perspectives. J Pharm Pharmaceut Sci 2006;

9 (3): 327-338.

276. Hardy JG, Wilson CG, Wood E. Drug delivery to the proximal colon, J

Pharmacol 1985; 37: 874-877.

277. Meyer JH, Dressman J, Fink AS, Amidon G. Effect of size and density on

gastric emptying of indigestible solids. Gastroenterology 1985; 89: 805-813.

278. Rodriguez M, Vila-Jato JL, Torres D. Design of a new multiparticulate system

for potential site specific and controlled drug delivery to the colonic region. J

Control Rel 1998; 55: 67-77.

279. Krishnaiah YSR, Satyanarayana V, Kumar BD, Karthikeyan RS, Bhaskar P.

In vivo pharmacokinetics in human volunteers: oral administered guar gum-

based colon- targeted 5- fluorouracil tablets. Eur J Pharm Sci 2003; 19: 355-

362.

280. Snoeck V, Huyghebaert N, Cox E, Vermeire A, Saunders J, Remon JP,

Verschooten F, Goddeeris BM. Gastrointestinal transit time of

nondisintegrating radio-opaque pellets in suckling and recently weaned

piglets. J of Control Rel 2004; 94: 143 15.

bibliography 1. ed., new york; marcell dekker;...

Documents